Doxazosin ER

Class
Adrenergic receptor blockers
Subclass
Selective α1-blockers
Substance name
Doxazosin mesylate ER
Brand names
Cardura XL®
Common formulations
Film-coated tablet
See also
Doxazosin (Cardura®)
Dosage and administration
Adults patients
Treatment of BPH
•
Start at: 4 mg PO daily
•
Maintenance: 4-8 mg PO daily
Titrate over 3-4 weeks based on response and tolerability.
Indications for use
Labeled indications
Adults
•
Treatment of BPH
Safety risks
Contraindications
Hypersensitivity to doxazosin or its components or other quinazolines
Concomitant use of other α-blockers
Warnings and precautions
Bowel obstruction
•
Use caution in patients with severe gastrointestinal narrowing.
Exacerbation of angina pectoris
•
Use caution in patients with congestive HF, angina pectoris, or recent myocardial infarction. Discontinue doxazosin if angina pectoris occurs or worsens.
Increased serum doxazosin levels
•
Use caution in patients taking potent CYP3A inhibitors. Monitor for hypotension.
Intraoperative floppy iris syndrome
•
Use caution in patients undergoing cataract surgery.
Mask symptoms of prostate cancer
•
Maintain a high level of suspicion, as prostate cancer can present with symptoms of BPH, and the two disorders frequently coexist. Exclude prostate cancer before initiating doxazosin.
Orthostatic hypotension, syncope
•
Use caution in all patients, especially those taking PDE5 inhibitors.
Priapism
•
Maintain a high level of suspicion, as an increased incidence has been reported in patients receiving doxazosin.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Continuous renal replacement
•
Use acceptable. No dose adjustment required.
Intermittent hemodialysis
•
Use acceptable. No dose adjustment required.
Peritoneal dialysis
•
Use acceptable. No dose adjustment required.
Hepatic impairment
Child-Pugh A (mild)
•
Use with caution. Monitor for hypotension.
Child-Pugh B (moderate)
•
Use with caution. Monitor for hypotension.
Child-Pugh C (severe)
•
Do not use.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Not intended for use in females. Evidence of fetal harm in animals.
Breastfeeding
Not intended for use in females.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
Hypotension, orthostatic hypotension, peripheral edema, abdominal pain, anxiety, asthenia, dizziness, dry mouth, dyspepsia, dyspnea, headache, myalgia, nausea, nosebleed, palpitations, somnolence, vertigo, respiratory tract infections
Uncommon < 1%
•
Arthralgia, chest pain, ↓ libido, diarrhea, hot flashes, muscle cramps, syncope, stroke, tachycardia
Unknown frequency
•
Agitation, bradycardia, bronchospasm, ↓ WBC count, ↓ platelet count, drug-induced liver injury, gynecomastia, ↑ liver enzymes, intraoperative floppy iris syndrome, jaundice, myocardial infarction, purpura, blurred vision, blurred vision, fatigue, hair loss, hematuria, hypoesthesia, loss of appetite, malaise, nocturia, paresthesia, polyuria, priapism, pruritus, bowel obstruction, skin rash, urinary frequency, vomiting, urticaria
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource